<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>brain lipid imbalance &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/brain-lipid-imbalance/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 23 Aug 2025 11:41:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>brain lipid imbalance &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Lipid Imbalance in Brain Drives Parkinson’s Dyskinesia</title>
		<link>https://bioengineer.org/lipid-imbalance-in-brain-drives-parkinsons-dyskinesia/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 23 Aug 2025 11:41:56 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[brain lipid imbalance]]></category>
		<category><![CDATA[L-DOPA-induced dyskinesia]]></category>
		<category><![CDATA[neurodegenerative lipid metabolism]]></category>
		<category><![CDATA[Parkinson’s disease dyskinesia]]></category>
		<category><![CDATA[primate model Parkinson’s research]]></category>
		<guid isPermaLink="false">https://bioengineer.org/lipid-imbalance-in-brain-drives-parkinsons-dyskinesia/</guid>

					<description><![CDATA[Emerging Insights into Lipid Dysregulation Illuminate Mechanisms Underlying L-DOPA-Induced Dyskinesia in Parkinson’s Disease Parkinson’s disease (PD) continues to challenge neuroscientists and clinicians alike, with its complex pathology and the often problematic side effects of standard treatment protocols. At the forefront of therapeutic strategies lies L-DOPA, a dopamine precursor that remains the most effective symptomatic treatment [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">257137</post-id>	</item>
	</channel>
</rss>
